American Institute for Advanced Investment Management LLP Has $6.41 Million Stock Position in Cencora, Inc. $COR

American Institute for Advanced Investment Management LLP lifted its holdings in shares of Cencora, Inc. (NYSE:COR) by 27.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,975 shares of the company’s stock after buying an additional 4,029 shares during the period. Cencora accounts for approximately 3.9% of American Institute for Advanced Investment Management LLP’s holdings, making the stock its 4th biggest position. American Institute for Advanced Investment Management LLP’s holdings in Cencora were worth $6,409,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Vanguard Group Inc. grew its position in shares of Cencora by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock valued at $7,976,681,000 after buying an additional 221,570 shares during the last quarter. State Street Corp grew its position in shares of Cencora by 9.3% during the 3rd quarter. State Street Corp now owns 9,190,316 shares of the company’s stock valued at $2,872,249,000 after buying an additional 782,911 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Cencora by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after buying an additional 821,098 shares during the last quarter. Boston Partners grew its position in shares of Cencora by 2.0% during the 3rd quarter. Boston Partners now owns 4,509,165 shares of the company’s stock valued at $1,409,152,000 after buying an additional 89,506 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Cencora by 3.0% during the 3rd quarter. Wellington Management Group LLP now owns 3,971,121 shares of the company’s stock valued at $1,241,094,000 after buying an additional 115,278 shares during the last quarter. Institutional investors own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on COR. Barclays upped their target price on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. JPMorgan Chase & Co. upped their target price on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. Finally, Robert W. Baird set a $415.00 target price on shares of Cencora in a research report on Tuesday, January 13th. Twelve equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $398.17.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This trade represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.38% of the stock is owned by company insiders.

Cencora Trading Up 0.0%

Cencora stock opened at $320.97 on Monday. The firm has a 50 day simple moving average of $345.36 and a 200-day simple moving average of $342.83. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. The stock has a market capitalization of $62.44 billion, a PE ratio of 38.58, a price-to-earnings-growth ratio of 1.50 and a beta of 0.72. Cencora, Inc. has a 12-month low of $271.00 and a 12-month high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s revenue was up 5.5% on a year-over-year basis. During the same period last year, the firm posted $3.73 earnings per share. As a group, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Stockholders of record on Friday, February 13th were issued a $0.60 dividend. The ex-dividend date was Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.